Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5799392 | 0.97 | KAT6A (0.54) | KAT6AOPRK1KMT2AMEN1MAOB | |
| SCHEMBL3972087 | 0.93 | OPRK1 (0.52) | KAT6AOPRK1KMT2AMEN1MAOB | |
| SCHEMBL12167864 | 0.86 | HRH1 (0.54) | KAT6AOPRK1KMT2AMEN1MAOB | |
| SCHEMBL931435 | 0.85 | EPHX2 (0.59) | KAT6AOPRK1KMT2AMEN1PARP10 | |
| Hydrochloric Acid SCHEMBL1808503 | 0.85 | HRH1 (0.53) | OPRK1KMT2AMEN1MAOBMAPK1 | |
| SCHEMBL3970957 | 0.84 | PARP10 (0.53) | KAT6AOPRK1KMT2AMEN1PARP10 | |
| SCHEMBL1807914 | 0.83 | OPRK1 (0.52) | OPRK1KMT2AMEN1EPHX2RAB9A | |
| SCHEMBL31130428 | 0.83 | KMT2A (0.48) | OPRK1KMT2AMEN1MAOBMAPK1 | |
| SCHEMBL930213 | 0.82 | EPHX2 (0.59) | KAT6AOPRK1KMT2AMEN1OPRM1 | |
| SCHEMBL30162751 | 0.82 | EPHX2 (0.59) | KAT6AOPRK1KMT2AMEN1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206723-A1 | METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS | Vettore, LLC | 2025-06-26 | — | — | US | claimed |
| EP-4568953-A1 | METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS | Vettore, LLC (US) | 2025-06-18 | — | — | EP | claimed |
| CN-119894883-A | Methods and processes for preparing MCT4 inhibitors | 维托尔股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| WO-2024031445-A1 | METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS | Vettore, LLC (US) | 2024-02-15 | — | — | WO | claimed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250206723-A1 | METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS | Vettore, LLC | 2025-06-26 | — | — | US | disclosed |
| EP-4568953-A1 | METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS | Vettore, LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119894883-A | Methods and processes for preparing MCT4 inhibitors | 维托尔股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-3551625-B1 | HETEROCYCLIC INHIBITORS OF MCT4 | VETTORE LLC (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024031445-A1 | METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS | Vettore, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| US-8697868-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | disclosed |
| EP-2119717-A1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-7501426-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
| EP-1758905-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| WO-2005085246-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DPP INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | KAT6A 2289/4885OPRK1 3547/4885KMT2A 3137/4885 |
| US-20250206723-A1 | METHODS AND PROCESSES FOR THE PREPARATION OF MCT4 INHIBITORS | SLC16A3, SLC16A1, SLC16A8 | KAT6A 1959/4885OPRK1 4542/4885KMT2A 1539/4885 |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | KAT6A 4533/4885OPRK1 436/4885KMT2A 2927/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | KAT6A 4494/4885OPRK1 610/4885KMT2A 3131/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | KAT6A 3761/4885OPRK1 2413/4885KMT2A 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.